Global Ovarian Cancer Drugs Market US$ 3.

8 Billion by 2021

The global ovarian cancer drugs market expected to reach US$ 3.8 billion by 2021, steadily growing at CAGR 20.5%
over the forecast period 2017-2021, mainly due to continued uptake and expected launces of the approved PARP
inhibitors, owing to their impressive efficacy, long treatment duration and the large number of treatment
opportunities in the first-line advanced setting.

Ovarian cancer is a cancer that forms in or on an ovary. In 2015, it was present in 1.2 million women and resulted
in 161,100 deaths worldwide. The risk of ovarian cancer increases in women who have ovulated more over their
lifetime. A diagnosis of ovarian cancer is confirmed through a biopsy of tissue, usually removed during surgery.
Treatment usually includes some combination of surgery, radiation therapy, and chemotherapy. Chemotherapy in
ovarian cancer typically consists of platins, a group of platinum-based drugs, combined with non-platins. Common
therapies can include paclitaxel, cisplatin, topotecan, doxorubicin, epirubicin, and gemcitabine. The vascular
endothelial growth factor (VEGF) inhibitor, bevacizumab (Avastin; Roche/ Genentech), is approved (excluding the
United States) as a first-line treatment in combination with standard chemotherapy. In Europe and the United States,
bevacizumab is also approved for recurrent ovarian cancer.

Browse Ovarian Cancer Drugs Market by Drug Class (Angiogenesis inhibitors, Poly (ADP Ribose) Polymerase
Inhibitors, Programmed Cell Death Protein 1 Ligand 1 Inhibitors), Pipeline Analysis by Target and Development Stage
and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/ovarian-cancer-drugs-market/

The global ovarian cancer drugs market segmentation is based on drug class (angiogenesis inhibitors, poly (ADP
ribose) polymerase inhibitors, programmed cell death protein 1 ligand 1 inhibitors), and pipeline analysis by target
and development stage.

The global ovarian cancer drugs market report provides market size (Revenue USD Million 2014 to 2021), market
share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global ovarian cancer drugs market research
report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of
LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest
of the World. The global ovarian cancer drugs market report also provides the detailed market landscape (market
drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in
the market by company overview, financial snapshot, key products, technologies and services offered, market share
analysis and recent trends in the global market.

Major players operating in the global ovarian cancer drugs market and profiled in this report include AbbVie,
AstraZeneca (Acerta Pharma), Boehringer Ingelheim GmbH, Five Prime Therapeutics, Gradalis, Incyte Corporation,
MacroGenics, Mateon Therapeutics, Merck KGaA, Novartis, Novogen, Inc., Oasmia Pharmaceuticals, Pfizer, Inc.,
PharmaMar (Chugai), and Roche (Genentech).

1. Drug Class
1.1. Angiogenesis inhibitors
1.2. Poly (ADP Ribose) Polymerase (PARP) Inhibitors
1.3. Programmed Cell Death Protein 1 Ligand 1 (PDL1) Inhibitors
1.4. Pipeline Analysis by Target and Development Stage

2. Geography (Region, Country)

2.1. North America (U.S., Canada)
2.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.3. Asia Pacific (Japan, China, India, Rest of APAC)
2.4. Latin America (Brazil, Mexico, Rest of LA)
2.5. Rest of the World

3. Company Profiles
 3.1. AbbVie
3.2. AstraZeneca (Acerta Pharma)
3.3. Boehringer Ingelheim GmbH
3.4. Five Prime Therapeutics
3.5. Gradalis
3.6. Incyte Corporation
3.7. MacroGenics
3.8. Mateon Therapeutics
3.9. Merck KGaA
3.10. Novartis
3.11. Oasmia Pharmaceuticals
3.12. Pfizer, Inc.
3.13. PharmaMar (Chugai)
3.14. Roche (Genentech)

To request Table of Contents and Sample Pages of this report visit:

https://www.ihealthcareanalyst.com/report/ovarian-cancer-drugs-market/

About Us

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting
grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client
assignments targeted at clients specific business objectives, information needs, time frame and budget. Please
contact us to receive a proposal for a proprietary single-client study.

Contact Us

iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com